Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Advisory Panels To See More Questions On Post-Market Safety Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

FDAAA authorities, such as REMS and the Safe Use initiative, direct FDA attention to appropriate use of drugs.

You may also be interested in...



Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree

Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting

Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree

Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting

Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree

FDA wants to gather long-term safety data in long acting beta-2 adrenergic agonist asthma drugs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel